Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-20-014525
Filing Date
2020-03-31
Accepted
2020-03-31 16:00:35
Documents
6
Period of Report
2020-05-12
Effectiveness Date
2020-03-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A nvus-def14a_20200512.htm DEF 14A 995850
2 GRAPHIC gh3a404nwwio000003.jpg GRAPHIC 4022
3 GRAPHIC gh3a404nwwio000002.jpg GRAPHIC 1900
4 GRAPHIC gh3a404nwwio000004.jpg GRAPHIC 113782
5 GRAPHIC gh3a404nwwio000005.jpg GRAPHIC 65814
6 GRAPHIC gh3a404nwwio000001.jpg GRAPHIC 4022
  Complete submission text file 0001564590-20-014525.txt   1258802
Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Novus Therapeutics, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36620 | Film No.: 20761736
SIC: 2834 Pharmaceutical Preparations